Cipla Q4 net profit down 3 percent on higher costs
MUMBAI (Reuters) - Drugmaker Cipla Ltd (CIPL.NS) on Thursday reported a 3 percent drop in fourth-quarter net profit, slightly below analysts' estimates due to higher raw material and employee expenses.
The company, among the world's largest suppliers of HIV/AIDS medicines, said January-March net profit was 2.61 billion rupees ($44.33 million), compared with 2.68 billion rupees a year earlier. Analysts on average expected 2.76 billion rupees, according to Thomson Reuters data.
Net sales rose about 15 percent to 21.94 billion rupees, while total expenses shot up 35 percent.
Cipla, one of the largest pharmaceutical companies in India, gets more than half its revenue through exports to nearly 180 overseas markets, including Africa, Latin America and the United States.
Shares of the company, down 6.4 percent so far this year, closed down 2 percent on Thursday, in line with the Nifty.($1 = 58.8750 rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Subhranshu Sahu)
- Tweet this
- Share this
- Digg this
- OPEC oil output hits highest since 2012 on Libya, Saudi-Reuters Survey
- Lightning, rain fail to deter resolute Hong Kong protesters
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State
- Obama, Modi work to deepen improving U.S.-India ties
- Obama, Modi discuss trade, climate, Islamic State at White House
U.S. President Barack Obama and Indian Prime Minister Narendra Modi worked to deepen improving ties between their countries on Tuesday, but emerged from their second meeting in two days with little in the way of major agreements. Story | Full Coverage
China final HSBC PMI steady in September on stronger global demand but risks remain Full Article